256 related articles for article (PubMed ID: 20200404)
1. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation.
Beer-Hammer S; Zebedin E; von Holleben M; Alferink J; Reis B; Dresing P; Degrandi D; Scheu S; Hirsch E; Sexl V; Pfeffer K; Nürnberg B; Piekorz RP
J Leukoc Biol; 2010 Jun; 87(6):1083-95. PubMed ID: 20200404
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of PI3-Kinase catalytic isoforms p110γ and p110δ in mice enhances the IL-17/G-CSF axis and induces neutrophilia.
Bucher K; Schmitt F; Mothes B; Blumendeller C; Schäll D; Piekorz R; Hirsch E; Nürnberg B; Beer-Hammer S
Cell Commun Signal; 2017 Jul; 15(1):28. PubMed ID: 28724384
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase.
Webb LM; Vigorito E; Wymann MP; Hirsch E; Turner M
J Immunol; 2005 Sep; 175(5):2783-7. PubMed ID: 16116162
[TBL] [Abstract][Full Text] [Related]
4. The p110 delta isoform of phosphatidylinositol 3-kinase controls the quality of secondary anti-Leishmania immunity by regulating expansion and effector function of memory T cell subsets.
Liu D; Uzonna JE
J Immunol; 2010 Mar; 184(6):3098-105. PubMed ID: 20154209
[TBL] [Abstract][Full Text] [Related]
5. Class I PI3K-mediated Akt and ERK signals play a critical role in FcεRI-induced degranulation in mast cells.
Takayama G; Ohtani M; Minowa A; Matsuda S; Koyasu S
Int Immunol; 2013 Apr; 25(4):215-20. PubMed ID: 23143475
[TBL] [Abstract][Full Text] [Related]
6. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.
Bilancio A; Okkenhaug K; Camps M; Emery JL; Ruckle T; Rommel C; Vanhaesebroeck B
Blood; 2006 Jan; 107(2):642-50. PubMed ID: 16179367
[TBL] [Abstract][Full Text] [Related]
7. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.
Okkenhaug K; Bilancio A; Farjot G; Priddle H; Sancho S; Peskett E; Pearce W; Meek SE; Salpekar A; Waterfield MD; Smith AJ; Vanhaesebroeck B
Science; 2002 Aug; 297(5583):1031-4. PubMed ID: 12130661
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Renal Ischemia-Reperfusion Injury in Mice by a Phosphoinositide 3-Kinase p110gamma-Specific Inhibitor.
Kim N; Woo DC; Joo SJ; Song Y; Lee JJ; Woo CW; Kim ST; Hong S; Cho YM; Han DJ
Transplantation; 2015 Oct; 99(10):2070-6. PubMed ID: 26431158
[TBL] [Abstract][Full Text] [Related]
9. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
Boller D; Schramm A; Doepfner KT; Shalaby T; von Bueren AO; Eggert A; Grotzer MA; Arcaro A
Clin Cancer Res; 2008 Feb; 14(4):1172-81. PubMed ID: 18281552
[TBL] [Abstract][Full Text] [Related]
10. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing.
Reif K; Okkenhaug K; Sasaki T; Penninger JM; Vanhaesebroeck B; Cyster JG
J Immunol; 2004 Aug; 173(4):2236-40. PubMed ID: 15294934
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease.
Maxwell MJ; Tsantikos E; Kong AM; Vanhaesebroeck B; Tarlinton DM; Hibbs ML
J Autoimmun; 2012 Jun; 38(4):381-91. PubMed ID: 22537464
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic signaling of class I PI3K isoforms.
Denley A; Kang S; Karst U; Vogt PK
Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
[TBL] [Abstract][Full Text] [Related]
13. p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells.
Tassi I; Cella M; Gilfillan S; Turnbull I; Diacovo TG; Penninger JM; Colonna M
Immunity; 2007 Aug; 27(2):214-27. PubMed ID: 17723215
[TBL] [Abstract][Full Text] [Related]
14. Ligand-selective signal transduction by two endogenous GnRH isoforms involves biased activation of the class I PI3K catalytic subunits p110β, p110γ, and p110δ in pituitary gonadotropes and somatotropes.
Pemberton JG; Stafford JL; Chang JP
Endocrinology; 2015 Jan; 156(1):218-30. PubMed ID: 25343277
[TBL] [Abstract][Full Text] [Related]
15. In vitro transformation of murine pro-B and pre-B cells by v-mpl, a truncated form of a cytokine receptor.
Fichelson S; Vigon I; Dusanter I; Charon M; Velu T; Baillou C; Gisselbrecht S; Lemoine FM
J Immunol; 1995 Feb; 154(4):1577-86. PubMed ID: 7836743
[TBL] [Abstract][Full Text] [Related]
16. CD22 regulates early B cell development in BOB.1/OBF.1-deficient mice.
Samardzic T; Gerlach J; Muller K; Marinkovic D; Hess J; Nitschke L; Wirth T
Eur J Immunol; 2002 Sep; 32(9):2481-9. PubMed ID: 12207332
[TBL] [Abstract][Full Text] [Related]
17. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.
Ramadani F; Bolland DJ; Garcon F; Emery JL; Vanhaesebroeck B; Corcoran AE; Okkenhaug K
Sci Signal; 2010 Aug; 3(134):ra60. PubMed ID: 20699475
[TBL] [Abstract][Full Text] [Related]
18. p110δ phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression.
Zhang TT; Makondo KJ; Marshall AJ
J Immunol; 2012 Apr; 188(8):3700-8. PubMed ID: 22422878
[TBL] [Abstract][Full Text] [Related]
19. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice.
Durand CA; Richer MJ; Brenker K; Graves M; Shanina I; Choi K; Horwitz MS; Puri KD; Gold MR
Autoimmunity; 2013 Feb; 46(1):62-73. PubMed ID: 23039284
[TBL] [Abstract][Full Text] [Related]
20. Arrested development: understanding v-abl.
Kerr LD
Bioessays; 1994 Jul; 16(7):453-5. PubMed ID: 7945272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
